Taxotere Hair-Loss Lawsuits Centralized
August 23, 2018
According to a notice made public August 15th, the New Jersey Supreme Court Justices in July granted multicounty litigation status to about 353 cases alleging Sanofi U.S. Services Inc., Sanofi-Aventis U.S. LLC, Sandoz Inc. and Actavis LLC failed to adequately warn consumers about the risk of permanent hair loss as a result of using the breast cancer drug Taxotere.
The lawsuits each assert that the drugmakers knew or should have known that Taxotere “causes and contributes to permanent disfigurement and hair loss,” but did not adequately warn of such risks, according to the patients’ centralization petition. The suits target the companies’ “wrongful conduct” in designing, manufacturing, distributing, labeling, advertising, marketing, promoting and selling the chemotherapy drug.
The cases will be heard by Judge James F. Hyland in Middlesex County, where 333 of the cases are pending.